LISOD 10TH ANNIVERSARY ONCOLOGY CONFERENCE
October 20, 2017 Kiev, Ukraine
Отель Hilton Kyiv,
бульвар Тараса Шевченка, 30
Персонализированная таргетная терапия и иммунотерапия рака: от базовой науки до клинического применения
Personalized targeted therapy and immunotherapy of cancer: from basic science to clinical application
Speakers
Yosef Yarden
One of the most famous scientists of Israel and the world. In 2017, received the highest award of Israel for outstanding achievements in the field of cancer research.
Professor Yarden's discoveries in molecular biology have allowed the development of new drugs for targeted therapy and immunotherapy, as well as new methods of treatment. In many ways, it was thanks to the scientific work of Yosef Yarden that Israel became one of the world leaders in the treatment of cancer.
Member of the Israeli Cancer Research Association; European Society for Cancer Research. The Weizmann Institute, Rehovot, Israel.
Avivit Peer
MD. Senior physician at the Cancer Department of Rambam Health Care Campus (Haifa, Israel). A well-known Israeli specialist in the field of oncourology.
Directions of activity: immunotherapy and targeted therapy for kidney, prostate, bladder cancer. Manages clinical research, which is conducted in the center of Rambam in conjunction with pharmaceutical companies.
Member of the Israeli Society for Clinical Oncology and Radiation Therapy; American Society of Clinical Oncology (ASCO).
Mor Moskovitz
MD. Doctor of the Thoracic Oncology Department at Rambam Health Care Campus (Haifa, Israel).
One of Israel's leading experts in the treatment of lung cancer. Active member of the Israeli Group for the Study of Lung Disease. Author of studies in the field of thoracic oncology.
A number of studies have been carried out in cooperation with the Society for the Study of Lung Cancer. She graduated with honors from the Faculty of Medicine of the Institute of Technology of Israel. She received training in thoracic oncology at the Princess Margaret Cancer Center in Toronto, (Canada).
Alla Vinnytska
MD. PhD. Known in Ukraine and in Europe oncogynecologist, doctor of medical sciences, LISOD Chief Medical Officer. Author of more than 200 scientific papers, co-author of more than 10 patents.
Member of the European Society of Oncogynecologists (ESGO), European Society of Medical Oncologists (ESMO), European Cervical Cancer Society (ECCA), American Society of Clinical Oncologists.
She possesses all methods of modern diagnosis and treatment of oncogynecologic diseases: endometrial cancer, cervical cancer, ovarian cancer, etc.
Abraham Kuten
MD. PhD. Professor of the Faculty of Medicine, Technion - Israel Institute of Technology (Haifa, Israel). Head of the oncology department of the Italian hospital in Haifa. He heads the Israeli Attestation Commission for the training and upgrading of the qualification level of oncologists.
One of the most authoritative experts in Israel and the world in the field of targeted and immunotherapy. Member of several international professional associations: EORTC, IMA, ISCORT, ASKO, ESMO.
Special interests: TSEI for MF, intraoperative radiation therapy, APBI, genetic predictors of the side effects of radiation therapy.
MD. Leading LISOD clinical oncologist. Received an award for outstanding services in the field of clinical oncology and radiotherapy. He made a significant contribution to the development of radiotherapy methods: research and development on radiotherapy planning for malignant tumors of the esophagus was included in the international guide "Principles and Practices of Radiation Oncology".
Member of international professional associations: IMA, ISCORT, ISGO, INOF, ESTRO, EORTC ROG, RCN.
Special interests: brachytherapy; modern 3-D radiation therapy of the gastrointestinal tract; intraoperative radiation therapy; palliative radiation therapy.
MD. PhD. Head of LISOD chemotherapy unit. Known in Ukraine oncohematologist, chemotherapist, and author of scientific works.
Under the leadership of Victoria Kosinova in the chemotherapy unit of the Hospital of Israeli Oncology effective treatment of patients with the use of newest original drugs is held, targeted therapy is widely and successfully used.
Conference Programm
Программа конференции
09.00 – 10.00 Регистрация участников, приветственный кофе.
10.00 – 10.15 Церемония открытия (проф. Ярден, проф. Кутен, почетные гости).
1-я сессия.
Модераторы: д-р Меир Заави, д-р Андрей Саулов.
10.20 – 10.35 Онкология сегодня: эра революции и эволюции (профессор Кутен).
10.40 – 11.20 Научная база таргетной терапии и иммунотерапии (профессор Ярден).
11.25 – 12.05 Таргетная терапия и иммунотерапия при урологическом раке (д-р Пир).
12.10 – 12.30 Кофе-пауза
2-я сессия.
Модераторы: проф. Авраам Кутен, д-р Цви Бернштейн.
12.35 – 13.15 Таргетная терапия и иммунотерапия при раке легких (д-р Московитц).
13.20 – 13.40 Иммунотерапия при немелкоклеточном раке легкого. Маркер PD-L1 (д-р Кошик).
13.45 – 14.00 Клинический случай лечения меланомы кожи с применением иммунотерапии (д-р Косинова, д-р Новиков).
14.00 – 15.15 Интерактивные презентации случаев: рак легких, урологические злокачественные опухоли.
15.15 Заключительные комментарии (профессор Авраам Кутен).
15.30 Обед
Conference Programm
09.00 – 10.00 Registration, welcome coffee.
10.00 – 10.15 Opening ceremony (Prof Yarden, Prof Kuten, special guests).
1-я session.
Moderators: Dr. Meir Zahavi, Dr. Andrey Saulov.
10.20 – 10.35 Oncology today: an era of revolution and evolution (Prof. Kuten).
10.40 – 11.20 The scientific basis of targeted therapy and immunotherapy (Prof. Yarden).
11.25 – 12.05 Targeted therapy and immunotherapy of urological cancer (Dr. Peer).
12.10 – 12.30 Coffee break
2-я session.
Moderators: Professor Abraham Kuten, Dr. Zvi Bernstein.
12.35 – 13.15 Targeted therapy and immunotherapy of lung cancer (Dr. Moskovitz).
13.20 – 13.40 Immunotherapy at small-cell lung cancer. PD-L1 marker (Dr. Koshik).
13.45 – 14.00 Clinical case of skin melanoma treatment with immunotherapy application (Dr. Kosinova, Dr. Novikov).
14.00 – 15.15 Interactive case presentations (lung cancer, urological malignancies).
15.15 Concluding remarks (Prof. Kuten).
15.30 Lunch
To take part